Free Trial

Enliven Therapeutics (ELVN) Competitors

Enliven Therapeutics logo
$21.23 -0.89 (-4.02%)
As of 02:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ELVN vs. ACLX, AKRO, MENS, KYMR, CRNX, NAMS, VKTX, LNTH, MIRM, and ADMA

Should you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Arcellx (ACLX), Akero Therapeutics (AKRO), Jyong Biotech (MENS), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Lantheus (LNTH), Mirum Pharmaceuticals (MIRM), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.

Enliven Therapeutics vs. Its Competitors

Enliven Therapeutics (NASDAQ:ELVN) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Enliven Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Enliven Therapeutics' return on equity of -29.15% beat Arcellx's return on equity.

Company Net Margins Return on Equity Return on Assets
Enliven TherapeuticsN/A -29.15% -27.88%
Arcellx -329.93%-43.04%-27.41%

Enliven Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

Enliven Therapeutics presently has a consensus target price of $41.20, indicating a potential upside of 93.15%. Arcellx has a consensus target price of $113.08, indicating a potential upside of 31.78%. Given Enliven Therapeutics' higher possible upside, equities analysts clearly believe Enliven Therapeutics is more favorable than Arcellx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enliven Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Arcellx
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, Enliven Therapeutics and Enliven Therapeutics both had 3 articles in the media. Arcellx's average media sentiment score of 0.80 beat Enliven Therapeutics' score of 0.34 indicating that Arcellx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enliven Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcellx
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Enliven Therapeutics has higher earnings, but lower revenue than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enliven TherapeuticsN/AN/A-$89.02M-$2.00-10.67
Arcellx$56.98M83.53-$107.35M-$3.42-25.09

Summary

Enliven Therapeutics beats Arcellx on 8 of the 15 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELVN vs. The Competition

MetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.27B$2.64B$6.14B$10.63B
Dividend YieldN/A57.79%5.72%4.85%
P/E Ratio-10.6823.9929.2427.24
Price / SalesN/A594.61494.13189.00
Price / CashN/A27.2425.8230.35
Price / Book3.365.3912.496.67
Net Income-$89.02M$33.06M$3.32B$276.25M
7 Day Performance6.12%2.01%2.07%0.10%
1 Month Performance12.51%10.96%8.78%3.84%
1 Year Performance-26.11%-1.53%63.73%33.07%

Enliven Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELVN
Enliven Therapeutics
1.9399 of 5 stars
$21.23
-4.0%
$41.20
+94.1%
-23.7%$1.26BN/A-10.6250
ACLX
Arcellx
2.6545 of 5 stars
$85.18
-1.2%
$112.69
+32.3%
-10.4%$4.73B$107.94M-24.9480
AKRO
Akero Therapeutics
3.7583 of 5 stars
$53.90
+0.4%
$73.38
+36.1%
+72.6%$4.31BN/A-26.9530
MENS
Jyong Biotech
N/A$55.75
+0.1%
N/AN/A$4.24BN/A0.0031Positive News
Gap Up
KYMR
Kymera Therapeutics
1.2129 of 5 stars
$59.32
-1.0%
$61.26
+3.3%
+30.4%$4.24B$47.07M-17.08170Analyst Forecast
CRNX
Crinetics Pharmaceuticals
4.4159 of 5 stars
$44.09
-0.8%
$74.45
+68.9%
-28.2%$4.16B$1.04M-10.74210Positive News
NAMS
NewAmsterdam Pharma
3.0388 of 5 stars
$36.86
-0.8%
$42.00
+13.9%
+95.5%$4.15B$45.56M-22.754News Coverage
Analyst Forecast
VKTX
Viking Therapeutics
4.0081 of 5 stars
$33.93
+0.1%
$86.42
+154.7%
-48.7%$3.81BN/A-22.1220Upcoming Earnings
LNTH
Lantheus
4.5931 of 5 stars
$54.35
-0.4%
$74.50
+37.1%
-51.5%$3.68B$1.53B14.41700
MIRM
Mirum Pharmaceuticals
4.1064 of 5 stars
$72.60
+0.6%
$76.50
+5.4%
+85.1%$3.65B$336.89M-60.00140
ADMA
ADMA Biologics
3.6697 of 5 stars
$14.87
+2.2%
$27.67
+86.1%
-6.9%$3.55B$426.45M17.31530Positive News

Related Companies and Tools


This page (NASDAQ:ELVN) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners